Connect with us

International

25+ stock market statistics 2022

The stock market is not just where shares of publicly listed companies trade, it’s perhaps the most vital component of the free market economy. While…

Published

on

The stock market is not just where shares of publicly listed companies trade, it’s perhaps the most vital component of the free market economy. While companies use the stock market to sell shares for the purposes of raising funds for their operations, there’s something else that is so essential to the sector. The market offers everyday investors the opportunity to buy shares and grow their investment.

However, the market is vast and it might pay for an investor to have a grasp of the broader market via access to the latest stock market news, right information, particularly knowledge of how the market works. Indeed, notable facts and statistics for key areas of the market can help one formulate important decisions before they are in stocks.

These 25+ most interesting stock market statistics for 2022 offer a great starting point heading into 2023. 

Top stock market stats for 2022

  • The global stock market capitalization is $105 trillion as of November 2022; it was $121 trillion in December 2021.
  • The United States stock market accounts for 44% of the world’s stock market capitalization.
  • The S&P 500 Index has declined nearly 17% year-to-date (November 2022) after a brutal bear market.
  • Almost 56% of American adults own stocks, while it’s 89% among the wealthiest households.
  • On average, a bear market lasts about 10 months while the average bull market takes nearly three years.

Global stock market statistics

1. The Frankfurt Stock Exchange is the oldest in the world

The world’s largest stock exchange may be in the United States, but Europe takes the mantle when it comes to the largest stock exchange by age. According to Statista, that honour goes to the Frankfurt Stock Exchange, founded in 1585 (437 years ago).

2. 11 stock exchanges were founded more than 100 years ago

The New York Stock Exchange and London Stock Exchange are second and third oldest stock exchanges in the world at 229 and 220 years old respectively. However, 11 stock exchanges have clocked 100+ years.

3. The global stock market capitalization hit a record $121 trillion

Despite the COVID-19 pandemic hit to the global equity market in 2020, the total market capitalization worldwide hit a peak of $121 trillion in late 2021. As of November 2022, the global market cap of all companies listed on stock exchanges was at $105 trillion. (Statista)

4. The United States accounts for 44% of total stock market cap

The major stock exchanges in the United States account for the greatest share of the stock market cap in 2022. As of November 2022, the total market capitalization of all publicly listed US stocks was $46.4 trillion, up from 40.7 trillion in 2020.

5. The top 5 countries account for 74% of stock market capitalization

The United States, China, Japan, Hong Kong, and Canada are the world’s largest stock markets, with the listed companies in these countries accounting for 74.43% of global market capitalization at over $92 trillion.

6. The New York Stock Exchange is the world’s largest stock exchange with over $23 trillion in market cap as of November 2022

The New York Stock Exchange in the United States is the world’s largest stock exchange. NYSE had a stock market capitalization of over $23 trillion as of November 2022. The NASDAQ and the Shanghai Stock Exchange completed the top 3 at the time with just under $20 trillion and $7 trillion respectively.

7. 19 of the world’s largest stock exchanges all have a market cap of $1 trillion or more

The New York Stock Exchange, Nasdaq Stock Exchange, Shanghai Stock Exchange, Tokyo Stock Exchange and the Shenzhen Stock Exchange are the world’s top 5 markets. A total of 19 stock exchanges around the world are ranked with $1 trillion or higher worth of market capitalization.

8. Apple is valued at $2.37 trillion, the world’s company by market capitalization

US-based technology giant Apple Inc. (NASDAQ: AAPL) is the world’s largest company by market capitalisation. The iPhone maker reached a landmark $3 trillion market capitalization in January 2022, and although it’s currently set at $2.37 trillion it still ranks as the world’s largest corporation by market cap.

9. Globally, only 4 companies have a market cap exceeding $1 trillion

The global trillion-dollar club in the stock market only has five members as of November 2022. Apple leads with over $2.3 trillion in market cap, having briefly hit $3 trillion earlier in the year. The others with $1 trillion+ are:

  • Saudi Aramco – $1.955 trillion 
  • Microsoft – $1.807 trillion
  • Alphabet (Google) – $1.234 trillion

According to CompaniesMarketCap, Amazon.com, Inc. (NASDAQ: AMZN) was out of the trillion-dollar club as of November 2022 with $942 billion.

10. The world’s most expensive stock is Warren Buffet’s Berkshire Hathaway

Warren Buffet’s Berkshire Hathaway Inc. (NYSE: BRK.A) is the world’s most expensive stock, valued at $477,019 as of 25th November 2022. The reason for this scenario is that the company has never done a stock split, which gives the single share that much value.

11. Over 80% of the stock market is automated

The growth in the stock market over the years has coincided with the introduction of numerous technology tweaks. One of these developments has been automation of trades, with 2022 stock market statistics showing that more than 80% of all trades on Wall Street are enhanced by advanced technological features that improve trading speed and accuracy among others.

Stock market performance statistics

12. About 86% of S&P 500 stocks traded above their 50-DMAs as of November 2022

As the tumultuous 2022 stock market moved towards its close, financial research group Bespoke Investment shared stats showing that more than 86% of S&P stocks were trading above the 50-day moving averages as of November. At the same time, 100% of S&P 500 Consumer Staples stocks had broken above their 50-DMAs.

13. The S&P 500 index has an average return of 11.8%

The S&P 500 has had an average return of 11.8% annually since 1957. The return in 2022 could however be lower given the bear market that sees the index nearly 17% down year-to-date.

14. On average, it takes 15 months for stock markets to recover from downturns of 20-40%

The average recovery time for the stock market after a 5-10% crash is historically 30 days or so. If the pullback places within 10-20%, it usually takes about four months for markets to recover. However, for a bigger sell-off in the 20-40%range, then markets have historically needed up to 15 months to recover.

15. Stocks rally an average 114% during bull markets

While stocks decline an average of 36% during bear markets, the bull market gains have averaged 114%.

16. An average bull market lasts 991 days, or about 2.7 years

Normally, bear markets are more short-lived lasting about 289 days, or approximately 9.6 months. In comparison, bull markets last an average of 991 days or about 2.7 years.

17 Recovery after a full blown market crash takes 13 years

Historically, various factors have contributed to the slow recovery of stock markets after a full blown crash as that seen in 2008. Usually, the market navigates the reversal for 151 months, or about 13 years.

18. The S&P 500 index closed at an all-time high of 4,766.18 in December 2021

The S&P 500 rose more than 26% through 2021 to 4,766.18 points in December for its highest value on record. These came amid a bull market run buoyed by easy money flowing through the economy following the COVID-19 pandemic. Historical data however shows the S&P 500 is 17% lower as of November 2022, and was oscillating around 3,976.

19. The S&P 500 rises an average of 8% one month after market correction

While stock market corrections are frequent and happen every two or so years, the S&P 500 has historically soared an average of 8% in the 30 days that follow the correction hitting a bottom. In fact, gains after the correction bottom have hit 24% or more on average just one year later.

20. The S&P 500 fell into correction territory in February 2022

In February 2022, the S&P 500 index fell into “correction” territory, declining more than 10% from its highs in December of the previous year.

21. There have been 20 stock corrections since 1980, including in 2022

Market corrections have historically occurred once every 2 years and involve declines of between 10% and 20% from a stock index’s last all-time high. There have been 20 stock market corrections since the 1980s, with only six occasions when a decline has surpassed 20% – this included the 2020 and 2022 corrections that were bearish. In 2020, the stock market declined 34% while in 2022, the S&P 500 fell more than 20% by June 2022 to enter bear market territory.

22. The third year of a US presidential term sees an average S&P 500 return of 12.8%

US stocks usually dip after the second year of a presidential term, dropping to an average of 4.8% from .5.2%. However, the third year has usually seen a huge spike, with average gains reaching 12.8%. The fourth year sees average S&P 500 returns of 5.7%.

Stocks ownership statistics

23. 89% of adults with an income of $100,000 or more own stocks

More people whose household income is $100,000 or higher invest in stocks. According to a Gallup survey of 2021, it was established that nearly 89% of adults in the above category owned stocks. In comparison, only 25% of those with a household income below $40,000 said they owned stocks.

24. 56% of Americans owned stocks in 2022

The number of Americans who reported owning stocks in 2022 was at 56% of the adult population, translating to about 145 million people. The percentage growth showed a very slight upside from the 55% of US adults who said they owned stocks in 2020. However, the numbers were still lower compared to the 63% in 2002 and 60% in 2007.

25. Millennials own just 2.6% of all US stocks

While Millennials have been shown to have invested more in cryptocurrencies for instance, the comparative percentage who own stocks is very small. According to data by the Federal Reserve, Millennials owned just 2.6% of all US stocks by Q2 of 2022, compared to Gen X’s 26.5% and Baby Boomers’ 55%.

26. Approximately 10% of American households own international stocks

Diversification is a key trend in 2022 and data shows nearly 10% of US households have added shares of various global companies to their portfolios

27. The wealthiest 10% of Americans own 89% of all US stocks

A small number of Americans, the wealthiest 10% of the population, owned 89% of all US stocks in 2022, according research details from late 2021. The top 1% on the rich list reportedly added $6.5 trillion to their wealth in stocks during the pandemic, far more than the $1.2 trillion gained by the bottom 90% of the population that owned 11% of all US stocks.

28. 89% of Warren Buffett’s portfolio is in 12 stocks

Warren Buffet has stakes in over forty securities. However, just 12 stocks make up 89% of the Oracle of Omaha’s portfolio. As of 15 November 2022, Berkshire Hathaway’s $347.2 billion was invested in just a dozen assets, with the top three being 39.6% in Apple (NASDAQ: AAPL), 11.2% in Bank of America (NYSE: BAC), and 9.2% in Chevron (NYSE: CVX).  

The rest of the top 12 of Buffet’s portfolio as of November 2022 are:

Key Takeaway

Stock market statistics don’t tell the whole story, but they offer snippets of what and how the market is. In 2022, the bear market has the S&P 500 looking to close in the red, but as stats show, the index has gained an average of 114% every bull market and has seen about 12% in average upside movement since 1957.

All in all, the market has a lot more statistics that the best course of action is for one to do their own due diligence for every company they consider a potential investment opportunity.

The post 25+ stock market statistics 2022 appeared first on Invezz.

Read More

Continue Reading

International

EY Eyes Comeback for Biopharma M&A

EY noted that the total value of biopharma M&A in 2022 was $88 billion, down 15% from $104 billion in 2021. The $88 billion accounted for most of the…

Published

on

A recent trickle of mergers and acquisitions (M&A) announcements in the billion-dollar-and-up range suggests that biopharma may be ready to resume dealmaking this year—although the value and number of deals isn’t expected to return to the highs seen just before the pandemic.

2022 ended with a handful of 10- and 11-figure M&A deals, led by Amgen’s $27.8 billion buyout of Horizon Therapeutics, announced December 13. The dealmaking continued into January with three buyouts announced on the first day of the recent J.P. Morgan Healthcare Conference: AstraZeneca agreed to acquire CinCor Pharma for up to $1.8 billion, while Chiesi Farmaceutici agreed to shell out up to $1.48 billion cash for Amryt, and Ipsen Group said it will purchase Albireo Pharma for $952 million-plus.

Biopharmas generated about $88 billion in M&A deals in 2022, down 15% from $104 billion in 2021. The $88 billion accounted for most of the $135 billion in 124 deals in the life sciences. The number of biopharma deals fell 17%, to 75 deals from 90. The other 49 deals totaling $47 million consisted of transactions in “medtech,” which includes diagnostics developers and companies specializing in “virtual health” such as telemedicine. [EY]
EY—the professional services firm originally known as Ernst & Young—recently noted that the total value of biopharma M&A in 2022 was $88 billion, down 15% from $104 billion in 2021 [See Chart]. The $88 billion accounted for most of the $135 billion in 124 deals in the life sciences. That $135 billion figure is less than half the record-high $313 billion recorded in 2019, including $261 billion in 70 biopharma deals.

The number of biopharma deals fell 17% to 75 deals from 90. EY’s numbers include only deals greater than $100 million. The other 49 deals totaling $47 million consisted of transactions in “medtech,” which includes diagnostics developers and companies specializing in “virtual health” such as telemedicine.

We expect this to be a more active year as the sentiment starts to normalize a little bit,” Subin Baral, EY Global Life Sciences Deals Leader, told GEN Edge.

Baral is not alone in foreseeing a comeback for biopharma M&A.

John Newman, PhD, an analyst with Canaccord Genuity, predicted last week in a research note that biopharma companies will pursue a growing number of smaller cash deals in the range of $1 billion to $10 billion this year. He said rising interest rates are discouraging companies from taking on larger blockbuster deals that require buyers to take on larger sums of debt.

“We look for narrowing credit spreads and lower interest rates to encourage larger M&A ($50 billion and more) deals. We do not anticipate many $50B+ deals that could move the XBI +5%,” Newman said. (XBI is the SPDR S&P Biotech Electronic Transfer Fund, one of several large ETFs whose fluctuations reflect investor enthusiasm for biopharma stock.)

Newman added: “We continue to expect a biotech swell in 2023 that may become an M&A wave if credit conditions improve.”

Foreseeing larger deals than Newman and Canaccord Genuity is PwC, which in a commentary this month predicted: “Biotech deals in the $5–15 billion range will be prevalent and will require a different set of strategies and market-leading capabilities across the M&A cycle.”

Those capabilities include leadership within a specific therapeutic category, for which companies will have to buy and sell assets: “Prepared management teams that divest businesses that are subscale while doubling down on areas where leadership position and the right to win is tangible, may be positioned to deliver superior returns,” Glenn Hunzinger, PwC’s U.S. Pharma & Life Science Leader, and colleagues asserted.

The Right deals

Rising interest and narrowing credit partially explain the drop-off in deals during 2022, EY’s Baral said. Another reason was sellers adjusting to the drop in deal valuations that resulted from the decline of the markets which started late in 2021.

Subin Baral, EY Global Life Sciences Deals Leader

“It took a little bit longer to realize the reality of the market conditions on the seller side. But on the buyer side, the deals that they were looking at were not just simply a valuation issue. They were looking at the quality of the assets. And you can see that the quality deals—the right deals, as we call them—are still getting done,” Baral said.

The right deals, according to Baral, are those in which buyers have found takeover targets with a strong, credible management team, solid clinical data, and a clear therapeutic focus.

“Rare disease and oncology assets are still dominating the deal making, particularly oncology because your addressable market continues to grow,” Baral said. “Unfortunately, what that means is the patient population is growing too, so there’s this increased unmet need for that portfolio of assets.”

Several of 2022’s largest M&A deals fit into that “right” category, Baral said—including Amgen-Horizon, Pfizer’s $11.6-billion purchase of Biohaven Pharmaceuticals and the $6.7-billion purchase of Arena Pharmaceuticals (completed in March 2022); and Bristol-Myers Squibb’s $4.1-billion buyout of Turning Point Therapeutics.

“Quality companies are still getting funded one way or the other. So, while the valuation dropped, people were all expecting a flurry of deals because they are still companies with a shorter runway of cash that will be running to do deals. But that really didn’t happen from a buyer perspective,” Baral said. “The market moved a little bit from what was a seller’s market for a long time, to what we would like to think of as the pendulum swinging towards a buyers’ market.”

Most biopharma M&A deals, he said, will be “bolt-on” acquisitions in which a buyer aims to fill a gap in its clinical pipeline or portfolio of marketed drugs through purchases that account for less than 25% of a buyer’s market capitalization.

Baral noted that a growing number of biopharma buyers are acquiring companies with which they have partnered for several years on drug discovery and/or development collaborations. Pfizer acquired BioHaven six months after agreeing to pay the company up to $1.24 billion to commercialize rimegepant outside the U.S., where the migraine drug is marketed as Nurtec® ODT.

“There were already some kind of relationships there before these deals actually happened. But that also gives an indication that there are some insights to these targets ahead of time for these companies to feel increasingly comfortable, and pay the valuation that they’re paying for them,” Baral said.

$1.4 Trillion available

Baral sees several reasons for increased M&A activity in 2023. First, the 25 biopharma giants analyzed by EY had $1.427 trillion available as of November 30, 2022, for M&A in “firepower”—which EY defines as a company’s capacity to carry out M&A deals based on the strength of its balance sheet, specifically the amount of capital available for M&A deals from sources that include cash and equivalents, existing debt, and market cap.

That firepower is up 11% from 2021, and surpasses the previous record of $1.22 trillion in 2014, the first year that EY measured the available M&A capital of large biopharmas.

Unlike recent years, Baral said, biopharma giants are more likely to deploy that capital on M&A this year to close the “growth gap” expected to occur over the next five years as numerous blockbuster drugs lose patent exclusivity and face new competition from lower-cost generic drugs and biosimilars.

“There is not enough R&D in their pipeline to replenish a lot of their revenue. And this growth gap is coming between 2024 and 2026. So, they don’t have a long runway to watch and stay on the sidelines,” Baral said.

This explains buyers’ interest in replenishing pipelines with new and innovative treatments from smaller biopharmas, he continued. Many smaller biopharmas are open to being acquired because declining valuations and limited cash runways have increased investor pressure on them to exit via M&A. The decline of the capital markets has touched off dramatic slowdowns in two avenues through which biopharmas have gone public in recent years—initial public offerings (IPOs) and special purpose acquisition companies (SPACs).

EY recorded just 17 IPOs being priced in the U.S. and Europe, down 89% from 158 a year earlier. The largest IPO of 2022 was Prime Medicine’s initial offering, which raised $180.3 million in net proceeds for the developer of a “search and replace” gene editing platform.

Another 12 biopharmas agreed to SPAC mergers with blank-check companies, according to EY, with the largest announced transaction (yet to close at deadline) being the planned $899 million merger of cancer drug developer Apollomics with Maxpro Capital Acquisition.

“For the smaller players, the target biotech companies, their alternate source of access to capital pathways such as IPOs and SPACs is shutting down on them. So how would the biotech companies continue to fund themselves? Those with quality assets are still getting funded through venture capital or other forms of capital,” Baral said. “But in general, there is not a lot of appetite for the biotech that is taking that risk.

Figures from EY show a 37% year-to-year decline in the total value of U.S. and European VC deals, to $16.88 billion in 2022 from $26.62 billion in 2021. Late-stage financing rounds accounted for just 31% of last year’s VC deals, down from 34% in 2021 and 58% in 2012. The number of VC deals in the U.S. and Europe fell 18%, to 761 last year from 930 in 2021.

The decline in VC financing helps explain why many smaller biopharmas are operating with cash “runways” of less than 12 months. “Depending on the robustness of their data, their therapeutic area, and their management, there will be a natural attrition. Some of these companies will just have to wind down,” Baral added.

M&A headwinds

Baral also acknowledged some headwinds that are likely to dampen the pace of M&A activity. In addition to rising interest rates and inflation increasing the cost of capital, valuations remain high for the most sought-after drugs, platforms, and other assets—a result of growing and continuing innovation.

Another headwind is growing regulatory scrutiny of the largest deals. Illumina’s $8 billion purchase of cancer blood test developer Grail has faced more than two years of challenges from the U.S. Federal Trade Commission and especially the European Commission—while Congress acted last year to begin curbing the price of prescription drugs and insulin through the “Inflation Reduction Act.”

Those headwinds may prompt many companies to place greater strategic priority on collaborations and partnerships instead of M&A, Baral predicted, since they offer buyers early access to newer technologies before deciding whether to invest more capital through a merger or acquisition.

“Early-stage collaboration, early minority-stake investment becomes increasingly important, and it has been a cornerstone for early access to these technologies for the industry for a long, long time, and that is not changing any time soon,” Baral said. “On the other hand, even on the therapeutic area side, early-stage development is still expensive to do in-house for the large biopharma companies because of their cost structure.

“So, it is efficient cost-wise and speed-wise to buy these assets when they reach a certain point, which is probably at Phase II onward, and then you can pull the trigger on acquisitions if needed,” he added.

The post EY Eyes Comeback for Biopharma M&A appeared first on GEN - Genetic Engineering and Biotechnology News.

Read More

Continue Reading

International

IMF Upgrades Global Growth Forecast As Inflation Cools

IMF Upgrades Global Growth Forecast As Inflation Cools

The International Monetary Fund published its latest World Economic Outlook on Monday,…

Published

on

IMF Upgrades Global Growth Forecast As Inflation Cools

The International Monetary Fund published its latest World Economic Outlook on Monday, painting a slightly less gloomy picture than three and a half months ago, as inflation appears to have peaked in 2022, consumer spending remains robust and the energy crisis following Russia’s invasion of Ukraine has been less severe than initially feared.

But, as Statista's Felix Richter notes, that’s not to say the outlook is rosy, as the global economy still faces major headwinds.

However, the IMF predicts the slowdown to be less pronounced than previously anticipated.

Global growth is now expected to fall from 3.4 percent in 2022 to 2.9 percent this year, before rebounding to 3.1 percent in 2024.

The 2023 growth projection is up from an October estimate of 2.7 percent, as the IMF sees far fewer countries facing recession this year and does no longer anticipates a global downturn.

Infographic: IMF Upgrades Global Growth Forecast as Inflation Cools | Statista

You will find more infographics at Statista

One of the reasons behind the cautiously optimistic outlook is the latest downward trend in inflation, which suggests that inflation may have peaked in 2022.

The IMF predicts global inflation to cool to 6.6 percent in 2023 and 4.3 percent in 2024, which is still above pre-pandemic levels of about 3.5 percent, but significantly lower than the 8.8 percent observed in 2022.

“Economic growth proved surprisingly resilient in the third quarter of last year, with strong labor markets, robust household consumption and business investment, and better-than-expected adaptation to the energy crisis in Europe,” Pierre-Olivier Gourinchas, the IMF’s chief economist, wrote in a blog post released along with the report.

“Inflation, too, showed improvement, with overall measures now decreasing in most countries—even if core inflation, which excludes more volatile energy and food prices, has yet to peak in many countries.”

The risks to the latest outlook remain tilted to the downside, the IMF notes, as the war in Ukraine could further escalate, inflation continues to require tight monetary policies and China’s recovery from Covid-19 disruptions remains fragile. On the plus side, strong labor markets and solid wage growth could bolster consumer demand, while easing supply chain disruptions could help cool inflation and limit the need for more monetary tightening.

In conclusion, Gourinchas calls for multilateral cooperation to counter “the forces of geoeconomic fragmentation”.

“This time around, the global economic outlook hasn’t worsened,” he writes. “That’s good news, but not enough. The road back to a full recovery, with sustainable growth, stable prices, and progress for all, is only starting.”

However, just because the 'trend' has shifted doesn't mean it's mission accomplished...

That looks an awful lot like Central Bankers' nemesis remains - global stagflation curb stomps the dovish hopes.

Tyler Durden Tue, 01/31/2023 - 14:45

Read More

Continue Reading

International

Nike Escalates Design Battle Against Lululemon

The sportswear giant is accusing lululemon of patent infringement.

Published

on

The sportswear giant is accusing lululemon of patent infringement.

The Gucci loafers. The Burberry  (BBRYF) trench coat. When it comes to fashion, having a unique design is everything. This is why brands spend millions both creating and protecting their signature looks and the reason, as in the case of Adidas  (ADDDF) , extricating a brand's design from creators who behave badly is a costly and difficult process.

There is also the constant effort to release new styles without infringing on another group's style. This week, sportswear giant Nike  (NKE) - Get Free Report filed a lawsuit accusing lululemon  (LULU) - Get Free Report of infringing on its patents in the shoe line that the Vancouver-based activewear company launched last spring.

After years of selling exclusively clothing, accessories and the odd yoga mat, lululemon expanded into the world of footwear with a running shoe it dubbed Blissfeel last March. These were soon followed by training shoe and pool slide styles known as Chargefeel, Strongfeel -- all three of the designs (including a Chargefeel Low and a Chargefeel Mid design) have been mentioned in the lawsuit as causing "economic harm and irreparable injury" to Nike.

Nike's History Of Suing Lululemon Over Design

The specific issue lies in the technology used to build the shoes. According to the lawsuit filed in Manhattan federal court, certain knitted elements, webbing and tubular structures are too similar to ones that had been used by Nike earlier.

Nike is keeping the amount it hopes to receive from lululemon under wraps but is insisting the company infringed on its patent when releasing a shoe line too similar to its own. Lululemon had previously talked about how its shoe line "far exceeded" its leaders' expectations both in terms of sales and ability to expand.

In a Q1 earnings call, chief executive Calvin McDonald said that the line "definitely had a lot more demand than we anticipated."

Nike has already tried to go after lululemon through the courts once before. In January 2022, it accused the company of infringing on six patents over its at-home Mirror Home Gym. As the world emerged out of the pandemic, lululemon has been billing it as a hybrid model between at-home and in-person classes. 

The lawsuit was also filed in the U.S. District Court in Manhattan but ultimately fizzled out.

When it comes to the shoe line lawsuit, Lululemon has been telling media outlets that "Nike's claims are unjustified" and the company "look[s] forward to proving [their] case in court."

Lululemon

Some More Examples Of Prominent Design Battles

In the fashion industry, design infringement accusations are common and rarely lead to high-profile rulings. While Nike has gone after the technology itself in both cases, lawsuits more often focus on the style or pattern on a given piece.

Shein, a China-based fast-fashion company that took on longtime leaders like H&M  (HNNMY)  and Fast Retailing  (FRCOF) 's Uniqlo with its bottom-of-the-barrel pricing, has faced numerous allegations from smaller and independent designers over the copying of designs -- in some cases not even from fashion designers but artists painting in local communities.

"They didn't remotely bother trying to change anything," U.K.-based artist Vanessa Bowman told the Guardian after seeing her painting of a local church appear on a sweater on Shein's website. "The things I paint are my garden and my little village: it’s my life. And they’ve just taken my world to China and whacked it on an acrylic jumper."

Read More

Continue Reading

Trending